Although this study is focused on 9p21 loss, we note that across multiple cancer cohorts, hemizygous deletion (9p21 LOH) is also associated with significantly shorter survival, reduced T-cell abundance and TCR repertoire diversity, lower abundance of T, B, CD8 T cells, cytotoxic lymphocytes, and lower rate of PD-L1 positivity, but with less magnitude compared to the corresponding levels observed in the 9p21-loss tumors. The gene discussed is CD8A; the disease is cancer.